Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE-Immunotherapeutics_resized
OSE (EPA:OSE) commences pivotal Phase III trial for Tedopi
Published by Jyoti Prakash, CFA

OSE Immunotherapeutics has announced the initiation of the much-awaited Phase III registrational study for lead asset Tedopi, the most advanced therapeutic cancer vaccine currently in development. The pivotal study, termed Artemia, will be a randomised, open-label trial evaluating Tedopi as a second-line monotherapy for HLA-A2 positive patients with metastatic non-small cell lung cancer. We note that the study will focus on patients with secondary resistance to immune checkpoint inhibitors, a cohort that saw the maximum benefit in the preceding Atalante-1 trial. Top-line results are expected by 2027.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.